MRK - CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients | Benzinga
CASI Pharmaceuticals Inc (NASDAQ:CASI) and BioInvent International AB announced preliminary efficacy data for BI-1206 in combination with rituximab in patients with relapsed/refractory (R/R) indolent Non-Hodgkin’s Lymphoma (iNHL) in the ongoing development program in China.
The Phase 1 dose-escalation study showed signs of clinical efficacy, with four partial responses (PR) and one complete response (CR) out of eight evaluable patients.
The results are consistent with the clinical data previously reported by BioInvent.
Among the responders in the study being conducted in China, one patient with relapsed Marginal Zone Lymphoma (MZL) who achieved CR maintained a durable complete remission for 20+ ...